http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
SHS법에 의한 TiC-Al₂O₃계 세라믹스의 합성 및 소결특성
이형복,김성수,편무실,최덕배 明知大學校 産業技術硏究所 1991 産業技術硏究所論文集 Vol.10 No.-
TiC-Al₂O₃ system powders were prepared by the self-propagating high temperature synthesis method from the mixture of metal titanium, carbon and alumina powder, Powder and sintering characterization of TiC-Al₂O₃ system were investigated. TiC-15wt% Al₂O₃ compacts sintered by hoy-pressing under the pressure of 20MPa at 1850 for 90 minutes showed 3-point bending strength of 724Mpa, ?? of ??????, hardness of 2450㎏/㎟ and relative density of 97%. The combustion mode of combustion wave showed steady-state up to 15wt% Al₂O₃, spin above 20wt% Al₂O₃ also combustion velocity was decreased with increasing of Al₂O₃ contents.
KIM, HUI-HUN,KIM, DUK-SIL,KIM, SUNG-WAN,LIM, SE-HYUN,KIM, DAE KEUN,SHIN, TAE-YONG,KIM, SANG-HYUN Spandidos Publications 2013 International journal of molecular medicine Vol.32 No.4
<P>Diospyros kaki (D. kaki) has been cultivated throughout Eastern Asia for hundreds of years. D. kaki contains various biological active compounds, such as amino acids, carotenoids, ?avonoids, tannins, catechins and vitamin A. Previous studies have shown that D. kaki has beneficial effects on homeostasis, constipation, hypertension, atherosclerosis and allergic dermatitis and is a good source of antioxidants, polyphenols and dietary ?ber. However, the anti-allergic and anti-inflammatory effects of D. kaki have not yet been elucidated. This study aimed to investigate the protective effects of the aqueous extract of Diospyros kaki (AEDK) on mast cell-mediated allergic inflammation and to determine its possible mechanisms of action by using in vitro and in vivo mast cell-based models. The cAMP and intracellular calcium levels were measured to clarify the mechanisms by which AEDK inhibits the release of histamine from mast cells. AEDK inhibited the release of histamine and β-hexosaminidase from mast cells by modulating cAMP and intracellular calcium levels. We also measured the expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β. AEDK decreased gene expression and the secretion of the pro-inflammatory cytokines, TNF-α and IL-1β by inhibiting nuclear factor-κB. In addition, AEDK inhibited systemic and cutaneous allergic reaction. The inhibitory effects of AEDK on allergic reaction and the release of histamine were found to be similar to those of disodium cromoglycate, a known anti-allergic drug. To isolate the active component of AEDK, activity-guided fractionation was performed, based on the inhibitory effects on systemic anaphylaxis. Catechin was identified as an active compound. The present findings provide evidence that AEDK inhibits allergic inflammation and suggest the therapeutic application of AEDK in allergic inflammatory disorders.</P>
Duk-Sil Kim,Sung-Wan Kim,Jun-Chul Kim,Ji-Hyung Cho,Joon-Hyuk Kong,Chang-Ryul Park 대한흉부외과학회 2011 Journal of Chest Surgery (J Chest Surg) Vol.44 No.1
Background: Mature autogenous arteriovenous fistulas have better long term patency and require fewer secondary interventions compared to arteriovenous prosthetic graft. Our Study evaluated vascular patency rates and incidence of interventions in autogenous arteriovenous fistulas and grafts. Material and Methods: A total of 166 vascular access operations were performed in 153 patients between December 2002 and November 2009. Thirty seven caeses were excluded due to primary access failure and loss of follow-up. One group of 92 autogenous arterioveous fistulas and the other group of 37 arteriovenous prosthetic grafts were evaluated retrospectively. Primary and secondary patency rates were estimated using the Kaplan-Meier method. Results: The primary patency rate (84%, 67%, 51%vs. 51%, 22%, 9% at 1, 3, 5 year; p=0.0000) and secondary patency rate (96%, 88%, 68% vs. 88%, 65%, 16%at 1. 3, 5 year; p=0.0009) were better in autogenous fistula group than prosthetic graft group. Interventions to maintain secondary patency were required in 23% of the autogenous fistula group (average 0.06 procedures/patient/year) and 65% of prosthetic graft group (average 0.21 procedures/patient/year). So the autogenous fistula group had fewer intervention rate than prosthetic graft group (p=0.01) The risk factor of primary patency was diabetus combined with ischemic heart disease and the secondary patency’s risk factor was age. Conclusion:Autogenous arteriovenous fistulas showed better performance compared to prosthetic grafts in terms of primary &secondary patency and incidence of interventions.
COMP-Angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury
Kim, Duk Hoon,Jung, Yu Jin,Lee, Ae Sin,Lee, Sik,Kang, Kyung Pyo,Lee, Tae Hwan,Lee, Sang Yong,Jang, Kyu Yun,Moon, Woo Sung,Choi, Kyu-Sil,Yoon, Kwon-Ha,Sung, Mi Jeong,Park, Sung Kwang,Kim, Won International Society of Nephrology 2009 Kidney international Vol.76 No.11
During sepsis endothelial dysfunction is an important pathogenetic mechanism in acute kidney injury (AKI). Lipopolysaccharide (LPS)-induced endotoxemia is associated with renal hemodynamic changes such as alterations of renal blood flow (RBF), vascular resistance, and glomerular filtration rate. We used adenoviral delivery of an engineered variant of native angiopoietin-1 (COMP-angiopoietin-1) containing anti-inflammatory and anti-permeability functions, to determine if regulation of renal endothelial cell dysfunction may have a beneficial role in preventing AKI during LPS-induced endotoxemia in mice. This treatment prevented the endotoxin-induced decrease of RBF and mean arterial pressure while improving glomerular filtration rate. Treatment also mitigated the effects of LPS on renal intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 protein expression, the number of ER-HR3-positive macrophages that infiltrated the kidney, serum nitrate/nitrite levels, renal inducible nitric oxide synthase protein expression, the induction of tubular epithelial reactive oxygen and nitrogen species, and renal microvascular permeability. Our findings show that COMP-angiopoietin-1, an endothelium-oriented therapeutic agent, protects against AKI caused by endotoxemia.
( Ji Hye Kim ),( Sang Hun Eum ),( Hyoung Woo Kim ),( Ji Won Min ),( Eun Sil Koh ),( Eun Jeong Ko ),( Hyung Duk Kim ),( Byung Ha Chung ),( Seok Joon Shin ),( Chul Woo Yang ),( Hye Eun Yoon ) 대한신장학회 2024 Kidney Research and Clinical Practice Vol.43 No.4
Background: Whether advanced age is associated with poor outcomes of elderly patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) is controversial. This study aimed to evaluate age effect and predictors for mortality in elderly AKI patients undergoing CRRT. Methods: Data of 480 elderly AKI patients who underwent CRRT were retrospectively analyzed. Subjects were stratified into two groups according to age: younger-old (age, 65-74 years; n = 205) and older-old (age, ≥75 years; n = 275). Predictors for 28-day and 90-day mortality and age effects were analyzed using multivariable Cox regression analysis and propensity score matching. Results: Urine output at the start of CRRT (adjusted hazard ratio [aHR], 0.99; 95% confidence interval [CI], 0.99-1.00; p = 0.04), operation (aHR, 0.53; 95% CI, 0.30-0.93; p = 0.03), and use of an intra-aortic balloon pump (aHR, 3.60; 95% CI, 1.18-10.96; p = 0.02) were predictors for 28-day mortality. Ischemic heart disease (aHR, 1.74; 95% CI, 1.02-2.98; p = 0.04) and use of a ventilator (aHR, 0.56; 95% CI, 0.36-0.89; p = 0.01) were predictors for 90-day mortality. The older-old group did not exhibit a higher risk for 28- day or 90-day mortality than the younger-old group in multivariable or propensity score-matched models. Conclusion: Advanced age was not a risk factor for mortality among elderly AKI patients undergoing CRRT, suggesting that advanced age should not be considered for therapeutic decisions in critically ill elderly patients with AKI requiring CRRT.
Je, In-Gyu,Choi, Hyun Gyu,Kim, Hui-Hun,Lee, Soyoung,Choi, Jin Kyeong,Kim, Sung-Wan,Kim, Duk-Sil,Kwon, Taeg Kyu,Shin, Tae-Yong,Park, Pil-Hoon,Khang, Dongwoo,Kim, Sang-Hyun Elsevier 2015 Toxicology and applied pharmacology Vol.287 No.2
<P><B>Abstract</B></P> <P>As the importance of allergic disorders such as atopic dermatitis and allergic asthma, research on potential drug candidates becomes more necessary. Mast cells play an important role as initiators of allergic responses through the release of histamine; therefore, they should be the target of pharmaceutical development for the management of allergic inflammation. In our previous study, anti-allergic effect of extracts of <I>Amomum xanthioides</I> was demonstrated. To further investigate improved candidates, 1,2,4,5-tetramethoxybenzene (TMB) was isolated from methanol extracts of <I>A. xanthioides</I>. TMB dose-dependently attenuated the degranulation of mast cells without cytotoxicity by inhibiting calcium influx. TMB decreased the expression of pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin (IL)-4 at both the transcriptional and translational levels. Increased expression of these cytokines was caused by translocation of nuclear factor-κB into the nucleus, and it was hindered by suppressing activation of IκB kinase complex. To confirm the effect of TMB <I>in vivo</I>, the ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) and IgE-mediated passive cutaneous anaphylaxis (PCA) models were used. In the ASA model, hypothermia was decreased by oral administration of TMB, which attenuated serum histamine, OVA-specific IgE, and IL-4 levels. Increased pigmentation of Evans blue was reduced by TMB in a dose-dependent manner in the PCA model. Our results suggest that TMB is a possible therapeutic candidate for allergic inflammatory diseases that acts through the inhibition of mast cell degranulation and expression of pro-inflammatory cytokines.</P> <P><B>Highlights</B></P> <P> <UL> <LI> TMB reduced the degranulation of mast cells. </LI> <LI> TMB inhibited the production of pro-inflammatory cytokines. </LI> <LI> TMB suppressed both active and passive anaphylaxis. </LI> <LI> Anti-allergic inflammatory effects of TMB might be due to the blocking IKK complex. </LI> <LI> TMB might be a candidate for the treatment of allergic inflammatory diseases. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Park, Eun Sil,Sung, Ki Woong,Baek, Hee Jo,Park, Kyung Duk,Park, Hyeon Jin,Won, Sung Chul,Lim, Do Hoon,Kim, Heung Sik The Korean Academy of Medical Sciences 2012 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.27 No.2
<P>The feasibility and effectiveness of tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) were evaluated in children younger than 3 yr of age with atypical teratoid/rhabdoid tumors (ATRT). Tandem HDCT/autoSCT was administered following six cycles of induction chemotherapy. Radiotherapy (RT) was administered if the tumor relapsed or progressed, otherwise, it was administered after 3 yr of age. Tumors relapsed or progressed during induction chemotherapy in 5 of 9 patients enrolled; 3 of these 5 received tandem HDCT/autoSCT as a salvage treatment. One patient died from sepsis during induction chemotherapy. The remaining 3 patients proceeded to tandem HDCT/autoSCT; however, 2 of these patients showed tumor relapse/progression after tandem HDCT/autoSCT. All 7 relapses/progressions occurred at primary sites even in patients with leptomeningeal seeding. Toxicities during tandem HDCT/autoSCT were manageable. A total of 5 patients were alive with a median follow-up of 20 (range 16-70) months from diagnosis. Four of 5 patients who received RT after relapse/progression are alive. The probability of overall survival at 3 yr from diagnosis was 53.3% ± 17.3%. Our tandem HDCT/autoSCT is feasible; however, early administration of RT prior to tandem HDCT/autoSCT should be considered to improve the outcome after tandem HDCT/autoSCT.</P>